The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Towa Bags Approval of Edirol AG through Partial Change of Its Version
Towa Pharmaceutical said on December 3 that it has gained approval for partial changes to its version of Chugai Pharmaceutical’s osteoporosis agent Edirol (eldecalcitol), making the product an authorized generic (AG) version. This is the first case of an AG…
To read the full story
Related Article
- Chugai’s Appeal Bid for Edirol Method-of-Use Patent Dismissed
December 14, 2022
- Chugai Challenges Ruling in Method-of-Use Patent Case for Edirol
June 10, 2022
- Tokyo Court Nixes Chugai’s Method-of-Use Patent Claim for Edirol
May 30, 2022
- Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
- Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
- Chugai Lifts Shipment Curbs for Edirol, Easing Active Vitamin D3 Shortages
September 13, 2021
- Edirol, Generic Drugs All Now Face Supply Curbs as Nichi-Iko Woes Spill Over
July 8, 2021
- Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
February 18, 2021
- Chugai Now Takes Nissan Chemical to Court over Edirol Patent, Seeks Damages from Sawai, Nichi-Iko Too
November 30, 2020
- Chugai Files Patent Litigation against Sawai, Nichi-Iko over Edirol Copies
June 1, 2020
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…